1. Finding the Right Option: Hormone Receptor-Positive Advanced Breast Cancer

2. Hormone Receptor-Positive Advanced Breast Cancer Introduction

3. Case Study 1

4. Case Study 1 (cont)

5. Response to Therapy

6. ASCO Key Guideline Recommendations for Hormone Receptor-Positive MBC

7. ASCO Key Guideline Recommendations for Hormone Receptor-Positive MBC (cont)

8. Endocrine Trials in First-Line MBC

9. Emerging Therapies for Hormone Receptor-Positive Breast Cancer

10. FALCON Anastrozole vs Fulvestrant in Hormone Receptor-Positive Advanced or MBC

11. FALCON Results

13. PALOMA-1 Palbociclib Plus Letrozole vs Letrozole Alone

14. PALOMA-1 Results

15. PALOMA-2 Palbociclib Plus Letrozole vs Letrozole Alone

16. PALOMA-2 Results

17. PALOMA-2 AE Summary

18. MONALEESA-2 Ribociclib Plus Letrozole vs Letrozole in Hormone Receptor-Positive Advanced Breast Cancer

19. MONALEESA-2 Results

20. MONALEESA-2 Safety Profile

21. Case Study 2

22. Case Study 2 (cont)

23. Options for Patients Who Have Disease Progression During/After Endocrine Therapy

24. PALOMA-3 Fulvestrant ± Palbociclib

25. PALOMA-3 Results

26. ESR1 Mutations

27. ESR1 Mutations Results

28. MONARCH 1 Abemaciclib

29. MONARCH1 Results

30. neoMONARCH Neoadjuvant Phase 2 Trial Interim Analysis

31. neoMONARCH Ki67 Results

32. Neoadjuvant Palbociclib With Anaztrozole

33. BOLERO-2 Everolimus Plus Exemestane vs Placebo Plus Exemestane

34. BOLERO-2 Results

35. SWISH Trial: Dexamethasone-Based Mouthwash for Stomatitis

36. Emerging Strategies

37. Conclusions

38. Abbreviations

39. Abbreviations (cont)

40. Abbreviations (cont)